Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains

Ya-Li Sang; Sheng Han; Shuwen Han; Christophe Pannecouque; De Clercq Erik; Chunlin Zhuang; Fen‐Er Chen

doi:10.1016/j.bioorg.2019.102974

Back

Shared by

De Clercq Erik

KU Leuven

Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains

Article 2019 en

Authors

YS
Ya-Li Sang
SH
Sheng Han
SH
Shuwen Han

Related publications

Article2007

Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains

Maria Letizia Barreca, Angela Rao, Laura De Luca, Nunzio Iraci, Anna‐Maria Monforte, Giovanni Maga, De Clercq Erik, Christophe Pannecouque, Jan Balzarini, Alba Chimirri

Article2007

Discovery of Novel Benzimidazolones as Potent Non‐Nucleoside Reverse Transcriptase Inhibitors Active Against Wild‐Type and Mutant HIV‐1 Strains.

Maria Letizia Barreca, Angela Rao, Laura De Luca, Nunzio Iraci, Anna‐Maria Monforte, Giovanni Maga, De Clercq Erik, Christophe Pannecouque, Jan Balzarini, Alba Chimirri

Article2018

Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1

Kaijun Jin, Hong Yin, De Clercq Erik, Christophe Pannecouque, Ge Meng, Fen‐Er Chen

Article2019

Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors

Sheng Han, Ya-Li Sang, Yan Wu, Yuan Tao, Christophe Pannecouque, De Clercq Erik, Chunlin Zhuang, Fen‐Er Chen

Article1993

HIV-1-Specific Reverse Transcriptase Inhibitors Show Differential Activity against HIV-1 Mutant Strains Containing Different Amino Acid Substitutions in the Reverse Transcriptase

Jan Balzarini, Anna Karlsson, María‐Jesús Pérez‐Pérez, Lotta Vrang, Johan Walbers, Hong Zhang, Bo Öberg, Anne‐Mieke Vandamme, Marı́a-José Camarasa, De Clercq Erik

Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains

Discussion(0)

Related publications

Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains

Discovery of Novel Benzimidazolones as Potent Non‐Nucleoside Reverse Transcriptase Inhibitors Active Against Wild‐Type and Mutant HIV‐1 Strains.

Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1

Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors

HIV-1-Specific Reverse Transcriptase Inhibitors Show Differential Activity against HIV-1 Mutant Strains Containing Different Amino Acid Substitutions in the Reverse Transcriptase